Emergence of drug resistance in human immunodeficiency virus type 1 infected patients from pune, India, at the end of 12 months of first line antiretroviral therapy initiation.
Discussion: The most common primary NNRTI resistance mutation was K103N/S which was observed in 6 study participants (K103N-5; K103S-1), which is also the most common mutation documented in another Indian study, whereas two other Indian studies found Y181C/V & G190A and V106M & Y181C, respectively, as the commonest NNRTI mutations.
Discussion: The other primary NNRTI resistance mutations that were seen in our study were V106M (2/19), Y181C (1/19), Y188L (2/19), and G190A (1/19).
Virological failure and HIV-1 drug resistance mutations among naive and antiretroviral pre-treated patients entering the ESTHER program of Calmette Hospital in Cambodia.
Result: Regarding the NNRTI mutations, V90L, K101E, K103N/S, V106I/M, V1791L were observed in both patients groups.
Optimization of the oligonucleotide ligation assay for the detection of nevirapine resistance mutations in Zimbabwean Human Immunodeficiency Virus type-1 subtype C.
PMID: 25239368
2014
Journal of virological methods
Abstract: An oligonucleotide ligation assay (OLA) designed to detect Human Immunodeficiency Virus type-1 (HIV)-drug-resistance to the nevirapine (NVP) selected mutations K103N, Y181C, V106M and G190A was used to evaluate 200 archived dried blood spots (DBS) from infected infants participating in the Zimbabwean Early Infant Diagnosis (EID) Program.
Introduction: Also, the probes for detection of V106M and G190A were not optimized for Zimbabwean HIV variants as indeterminate OLA results appeared to be caused by a variety of polymorphisms that could not be readily incorporated into new probes.
Introduction: An economical oligonucleotide ligation assay (OLA) was developed to detect mutations generally associated with HIV-DR to NVP (K103N,
A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses.
Discussion: The NNRTI-resistance mutation V106M is more common in subtype C viruses because it requires one nucleotide change compared with two changes in other subtypes.
"Description of the L76V resistance protease mutation in HIV-1 B and ""non-B"" subtypes."
Discussion: Differences have been previously observed in the genetic barrier to resistance in mutations associated with resistance to non nucleoside reverse transcriptase inhibitors (NNRTI) for the A98S and V106M mutations between HIV-1 B and C subtypes, or in mutations associated with resistance to integrase inhibitors between B and CRF02_AG subtypes.
Human APOBEC3G-mediated hypermutation is associated with antiretroviral therapy failure in HIV-1 subtype C-infected individuals.
PMID: 23443042
2013
Journal of the International AIDS Society
Table: V106M
Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy.
Restriction fragment mass polymorphism (RFMP) analysis based on MALDI-TOF mass spectrometry for detecting antiretroviral resistance in HIV-1 infected patients.
PMID: 23480551
2013
Clinical microbiology and infection
Abstract: The concordance rates between the RFMP and direct sequencing assays for the examined codons were 97% (K65R), 97% (T69Ins/D), 97% (L74VI), 97% (K103N), 96% (V106AM), 97% (Q151M), 97% (Y181C), 97% (M184VI) and 94% (T215YF) in the reverse transcriptase coding region, and 100% (D30N), 100% (M46I), 100% (G48V), 100% (I50V), 100% (I54LS), 99% (V82A), 99% (I84V) and 100% (L90M) in th
Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009).
Abstract: Major mutations in reverse transcriptase included K65R(n = 1), L74I(n = 1), K103N(n = 19), V106M(n = 4), Y181C(n = 2), M184V(n = 4), and K219E/R(n = 2).
Table: V106M
Figure: Histogram showing number of women with drug resistant HIV infection that had each of the following protease inhibitor (PI), nucleoside reverse transcriptase inhibitor (NRTI) or non-nucleoside reverse transcriptase inhibitor ( PMID: 23660583
2013
Journal of virological methods
Abstract: Known proportions of mutant and wild-type plasmids were used to optimize a multiplex OLA for detection of K103N, Y181C, K65R, and M184V in HIV subtypes B and C, and V106M and G190A in subtype C.
Method: Amplicons from plasmid controls and specimens were tested in duplicate by SPX- and MPX-OLA using validated HIV subtype B- and subtype C-specific probes for detection of drug-resistance mutations K65R, M184V, K103N, <
Result: Slightly more V106M, Y181C, and G190A mutants were detected by MPX- compared to SPX-OLA across the filter paper and plasma specimens.
HIV mutation literature information.
PMID: 
2014
ISRN AIDS
Browser Board
Co-occurred Entities
Filtrator
ViMRT